Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640353 | 0.88 | DAO (0.41) | RAB9ANPC1SMN1; SMN2ADORA3MAPT | |
| SCHEMBL114060 | 0.85 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2ADORA3MAPT | |
| SCHEMBL114057 | 0.85 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2ADORA3MAPT | |
| SCHEMBL490098 | 0.79 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2MAPTTSHR | |
| SCHEMBL5634559 | 0.76 | ADORA3 (0.38) | RAB9ANPC1SMN1; SMN2ADORA3MAPT | |
| SCHEMBL1520968 | 0.75 | SMN1; SMN2 (0.57) | RAB9ANPC1SMN1; SMN2MAPTTSHR | |
| SCHEMBL10847008 | 0.73 | SMN1; SMN2 (0.53) | RAB9ANPC1SMN1; SMN2ADORA3MAPT | |
| SCHEMBL112782 | 0.72 | HPGD (0.59) | RAB9ASMN1; SMN2MAPTTSHRPKM | |
| SCHEMBL1520770 | 0.72 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2MAPTTSHR | |
| SCHEMBL18499086 | 0.69 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050107403-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | HAWLEY RONALD C (US) | 2005-05-19 | — | — | US | disclosed |
| US-6846828-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2005-01-25 | — | — | US | disclosed |
| EP-1444223-A1 | AMINOPYRIMIDINES AND -PYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20030144303-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | SYNTEX (U.S.A.) LLC | 2003-07-31 | — | — | US | disclosed |
| WO-2003040131-A1 | AMINOPYRIMIDINES AND PYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107403-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | IL6, DPYD, TYMP | RAB9A 4495/4885NPC1 4212/4885SMN1; SMN2 3326/4885 |
| US-20030144303-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | IL6, DPYD, TYMP | RAB9A 4525/4885NPC1 4028/4885SMN1; SMN2 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.